FIELD: medicine; neuropsychology.
SUBSTANCE: group of inventions is intended for using a therapeutically effective amount of a combination (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine or pharmaceutically acceptable salts thereof, where (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine, which are taken at ratio of 0.5:1 to 20:1, in the treatment of hyperkinetic movement disorder. Also disclosed is the use of an effective amount of (−)-α-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof in a composition, method of treating hyperkinetic movement disorder and a method of improving the efficacy of the composition.
EFFECT: technical result of the group of inventions is an increase in the efficiency of the combination of (+)- and (−)-α-dihydrotetrabenazine with respect to reduced motor activity in amphetamine-induced rats than taken separately (+)-α-dihydrotetrabenazine, despite the fact that, as previously reported, (−)-α-dihydrotetrabenazine is a weak inhibitor of VMAT2.
22 cl, 2 tbl, 2 ex, 12 dwg
